From Dealroom · · 50s
China's Tushen Zhihe raises hundreds of millions of yuan for AI protein design
Chinese AI startup Tushen Zhihe secures hundreds of millions of yuan in funding for drug design innovation.
In brief
Chinese AI startup Tushen Zhihe secures hundreds of millions of yuan in funding for drug design innovation. Tushen Zhihe, a Chinese AI protein-design startup, raised hundreds of millions of yuan across Pre-A and Pre-A+ rounds to advance drug development through AI. Originally reported by Dealroom.
Funding Round
Tushen Zhihe raised hundreds of millions of yuan across Pre-A and Pre-A+ rounds with Shanghai STVC Group leading the Pre-A round.
AI Drug Design Focus
The company builds ai models to design proteins for drugs targeting hard-to-drug targets like gpcrs, antibodies, and cyclic peptides.
Next Steps

Tushen Zhihe will push in-house pipelines toward investigational new drug filings, upgrade ai tools, and expand teams to partner with drugmakers.
In short
Tushen Zhihe, a Chinese AI protein-design startup, raised hundreds of millions of yuan across Pre-A and Pre-A+ rounds to advance drug development through AI.
Read the TL;DR — this story on one card.





